Natera (NASDAQ:NTRA) CEO Sells $1,565,251.80 in Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Chapman sold 3,801 shares of the company’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $411.80, for a total transaction of $1,565,251.80. Following the completion of the transaction, the chief executive officer owned 87,431 shares of the company’s stock, valued at approximately $36,004,085.80. The trade was a 4.17% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Steven Leonard Chapman also recently made the following trade(s):

• On Wednesday, October 28th, Steven Chapman sold 3,430 shares of Natera stock. The stock was sold at an average price of $426.34, for a total transaction of $1,462,346.20.
• On Tuesday, October 27th, Steven Chapman sold 2,264 shares of Natera stock. The shares were sold at an average price of $406.00, for a total transaction of $919,184.00.
• On Thursday, October 1st, Steven Chapman sold 1,273 shares of Natera stock. The shares were sold at an average price of $413.31, for a total transaction of $526,143.63.
• On Tuesday, September 1st, Steven Chapman sold 1,698 shares of Natera stock. The shares were sold at an average price of $320.99, for a total value of $545,041.02.

Natera Stock Up 0.6%

Shares of NASDAQ:NTRA traded up $2.40 on Wednesday, reaching $391.03. 2,799,993 shares of the company’s stock were exchanged, compared to its average volume of 1,672,252. Natera, Inc. has a fifty-two week low of $181.00 and a fifty-two week high of $437.41. The business’s 50-day moving average is $380.30 and its two-hundred day moving average is $268.64.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. The firm had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The firm’s revenue for the quarter was up 37.7% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.74) earnings per share. Equities analysts anticipate that Natera, Inc. will post -1.14 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. BTIG Research raised their price target on Natera from $320.00 to $430.00 and gave the company a “buy” rating in a report on Tuesday, October 27th. Leerink Partners set a $330.00 target price on shares of Natera in a research report on Friday, August 7th. Canaccord Genuity Group raised their target price on shares of Natera from $375.00 to $500.00 and gave the company a “buy” rating in a research note on Monday, October 19th. Morgan Stanley increased their price target on shares of Natera from $355.00 to $435.00 and gave the company an “overweight” rating in a report on Monday, October 12th. Finally, Guggenheim increased their price target on Natera from $360.00 to $475.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Natera presently has an average rating of “Moderate Buy” and an average price target of $394.31.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in NTRA. SYM FINANCIAL Corp grew its position in Natera by 1.7% during the third quarter. SYM FINANCIAL Corp now owns 1,897 shares of the medical research company’s stock worth $784,000 after buying an additional 32 shares in the last quarter. Versant Capital Management Inc lifted its stake in shares of Natera by 4.6% in the 3rd quarter. Versant Capital Management Inc now owns 815 shares of the medical research company’s stock valued at $337,000 after acquiring an additional 36 shares during the last quarter. AlphaCentric Advisors LLC boosted its holdings in shares of Natera by 3.0% during the third quarter. AlphaCentric Advisors LLC now owns 1,432 shares of the medical research company’s stock worth $592,000 after purchasing an additional 42 shares during the period. VestGen Advisors LLC boosted its holdings in Natera by 3.1% in the third quarter. VestGen Advisors LLC now owns 1,460 shares of the medical research company’s stock valued at $603,000 after acquiring an additional 44 shares in the last quarter. Finally, Parallel Advisors LLC raised its stake in Natera by 5.5% in the first quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock worth $181,000 after buying an additional 47 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Key Stories Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Medicare coverage for Signatera in HCC could improve patient access and support adoption of Natera’s cancer-monitoring tests. The coverage milestone adds to the commercial opportunity for its oncology business. Natera Medicare coverage for Signatera in HCC
• Positive Sentiment: New ESMO oncology evidence was described as broadening the case for Natera’s cancer-testing portfolio, potentially reinforcing the longer-term growth story. ESMO data broaden Natera’s oncology case
• Neutral Sentiment: Natera was expected to report earnings on November 5, making results and management’s outlook a near-term catalyst; the preview article did not provide reported results. Natera earnings preview
• Neutral Sentiment: The reported analyst consensus price target was $394.31, close to the share price cited in the provided market background, suggesting limited implied upside from that target alone. Natera consensus target price
• Neutral Sentiment: CFO Michael Brophy sold 1,178 shares under a pre-arranged Rule 10b5-1 plan and retained 48,480 shares. The scheduled nature and relatively small size of the sale may temper its significance as a signal about management’s outlook. CFO share sale report

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.